Definium Therapeutics (DFTX) Other Non Operating Income (2019 - 2026)
Definium Therapeutics (DFTX) reported Other Non Operating Income of -$17.9 million for Q1 2026, down 93994.74% year-over-year from N/an in Q1 2025, and down 13547.33% on a QoQ basis from -$131000.0 in Q4 2025.
Definium Therapeutics (DFTX) has 8 years of Other Non Operating Income data on file, last reported at -$17.9 million in Q1 2026.
- Quarterly Other Non Operating Income fell 93994.74% year-over-year to -$17.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$39.7 million (down 214.22% YoY) and the FY2025 annual result came in at -$131000.0, down 105.16% from the prior year.
- Other Non Operating Income retreated to -$17.9 million in Q1 2026 per DFTX's latest filing, from -$131000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $18.6 million in Q2 2024 and bottomed at -$32.2 million in Q1 2024.
- The 5-year median for Other Non Operating Income is $54000.0 (2022), against an average of -$1.9 million.
- The widest annual swing landed in 2024, when Other Non Operating Income jumped 7431.98%; it then plunged 93994.74% in 2026.
- Tracing DFTX's Other Non Operating Income over 5 years: stood at $101000.0 in 2022, then jumped by 141.58% to $244000.0 in 2023, then surged by 1959.43% to $5.0 million in 2024, then slumped by 102.61% to -$131000.0 in 2025, then slumped by 13547.33% to -$17.9 million in 2026.
- Per Business Quant, the three latest DFTX Other Non Operating Income figures stand at -$17.9 million (Q1 2026), -$131000.0 (Q4 2025), and -$21.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.88 Mn |
| Dec 31, 2025 | -131,000.00 |
| Sep 30, 2025 | -21.60 Mn |
| Jun 30, 2025 | -49,000.00 |
| Mar 31, 2025 | -19,000.00 |
| Dec 31, 2024 | 5.03 Mn |
| Sep 30, 2024 | 11.11 Mn |
| Jun 30, 2024 | 18.60 Mn |
| Mar 31, 2024 | -32.20 Mn |
| Dec 31, 2023 | 244,000.00 |
| Sep 30, 2023 | 3.69 Mn |
| Jun 30, 2023 | 247,000.00 |
| Mar 31, 2023 | -52,000.00 |
| Dec 31, 2022 | 101,000.00 |
| Sep 30, 2022 | 138,000.00 |
| Jun 30, 2022 | -14,000.00 |
| Mar 31, 2022 | 54,000.00 |
| Dec 31, 2021 | -180,000.00 |
| Sep 30, 2021 | -40,000.00 |
| Jun 30, 2021 | -35,000.00 |
| Mar 31, 2021 | 8,000.00 |
| Dec 31, 2020 | 639,000.00 |
| Sep 30, 2020 | -58,000.00 |
| Jun 30, 2020 | 209,000.00 |
| Mar 31, 2020 | -660,000.00 |
| Dec 31, 2019 | 28,000.00 |